Suppr超能文献

起始抗逆转录病毒治疗时基线病毒载量非常高的HIV感染患者的病毒学演变

[Virological evolution of patients with HIV infection that start antiretroviral therapy with a very high baseline viral load].

作者信息

Kral Alejandro, Wolff Marcelo, Villalobos Humberto, Segovia Christian, Cortés Claudia P

机构信息

Hospital Clínico San Borja Arriarán, Fundación Arriarán, Universidad de Chile, Chile.

Oficina de Investigación, Escuela de Medicina, Universidad de Valparaíso, Chile.

出版信息

Rev Chilena Infectol. 2021 Dec;38(6):783-789. doi: 10.4067/s0716-10182021000600783.

Abstract

BACKGROUND

The degree of viral suppression in HIV patients who start antiretroviral therapy (ART) with very high viral loads (CV) is unknown.

AIM

To know the percentage of viral suppression in HIV patients who start ART with CV ≥ 500,000 copies/mL at 96 weeks.

METHOD

Retrospective study. Patients who started ART with a CV ≥ 500,000 copies/mL between 2008 and 2018 were included, stratifying on the basis of a logarithmic scale. The percentage of viral suppression and the variables associated with this outcome were determined.

RESULTS

221 patients were included. The median age and CV were 43 years and 6.0 log, respectively, with the majority (37%) being in stage C3 at the start of ART. 48.8 and 87.7% of the patients achieved viral suppression at one year and two years of follow-up, respectively. It was observed that the older the immunosuppression, and the higher CV, the longer the time to achieve undetectability. Virological failure was only demonstrated in three patients.

DISCUSSION

Patients with HIV infection who start ART with very high CVs take longer to achieve viral suppression, which is proportional to the magnitude of this and the degree of immunosuppression, without this entailing a greater risk of virological failure.

摘要

背景

开始接受抗逆转录病毒治疗(ART)时病毒载量非常高(CV)的HIV患者的病毒抑制程度尚不清楚。

目的

了解在96周时开始接受ART且CV≥500,000拷贝/毫升的HIV患者的病毒抑制百分比。

方法

回顾性研究。纳入2008年至2018年间开始接受ART且CV≥500,000拷贝/毫升的患者,并根据对数尺度进行分层。确定病毒抑制百分比以及与该结果相关的变量。

结果

纳入221例患者。中位年龄和CV分别为43岁和6.0 log,大多数患者(37%)在开始ART时处于C3期。在随访一年和两年时,分别有48.8%和87.7%的患者实现了病毒抑制。观察到免疫抑制越严重、CV越高,达到病毒检测不到所需的时间越长。仅3例患者出现病毒学失败。

讨论

开始接受ART时CV非常高的HIV感染患者实现病毒抑制所需的时间更长,这与CV的大小和免疫抑制程度成正比,且这并不意味着病毒学失败的风险更高。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验